Consolidated Balance Sheets - USD ($) $ in Millions		Sep. 30, 2024	Sep. 30, 2023
Current assets
Cash and cash equivalents		$ 300	$ 417
Accounts receivable - Notes A and H	[1]	243	338
Inventories - Note A		545	626
Other assets		107	125
Total current assets		1,195	1,506
Property, plant and equipment - Note F
Cost		3,316	3,211
Accumulated depreciation		2,013	1,838
Net property, plant and equipment		1,303	1,373
Goodwill - Note G		1,381	1,362
Intangibles - Note G		751	886
Operating lease assets, net - Note J		114	122
Restricted investments - Note E		295	290
Asbestos insurance receivable - Notes A and M	[2]	132	127
Deferred income taxes - Note K		210	22
Other assets - Note I		264	251
Total noncurrent assets		4,450	4,433
Total assets		5,645	5,939
Current liabilities
Short-term debt - Note H		0	16
Trade and other payables		214	210
Accrued expenses and other liabilities		256	208
Current operating lease obligations - Note J		20	22
Total current liabilities		490	456
Noncurrent liabilities
Long-term debt - Note H		1,349	1,314
Asbestos litigation reserve - Note M		414	427
Deferred income taxes - Note K		29	148
Employee benefit obligations - Note L		110	100
Operating lease obligations - Note J		99	106
Other liabilities - Note I		286	291
Total noncurrent liabilities		2,287	2,386
Commitments and contingencies - Notes J and M
Equity - Notes N and O
Common stock, par value $.01 per share, 200 million shares authorized Issued 47 million and 51 million shares in 2024 and 2023		1	1
Paid-in capital			4
Retained earnings		3,315	3,595
Accumulated other comprehensive loss		(448)	(503)
Total equity		2,868	3,097
Total liabilities and equity		$ 5,645	$ 5,939

[1] Accounts receivable includes an allowance for credit losses of $2 million and $3 million at September 30, 2024 and 2023, respectively.

[2] Asbestos insurance receivable includes an allowance for credit losses of $2 million at both September 30, 2024 and 2023.